Literature DB >> 23515282

HDL and cholesterol: life after the divorce?

Kasey C Vickers1, Alan T Remaley.   

Abstract

For decades, HDL and HDL-cholesterol (HDL-C) levels were viewed as synonymous, and modulation of HDL-C levels by drug therapy held great promise for the prevention and treatment of cardiovascular disease. Nevertheless, recent failures of drugs that raise HDL-C to reduce cardiovascular risk and the now greater understanding of the complexity of HDL composition and biology have prompted researchers in the field to redefine HDL. As such, the focus of HDL has now started to shift away from a cholesterol-centric view toward HDL particle number, subclasses, and other alternative metrics of HDL. Many of the recently discovered functions of HDL are, in fact, not strictly conferred by its ability to promote cholesterol flux but by the other molecules it transports, including a diverse set of proteins, small RNAs, hormones, carotenoids, vitamins, and bioactive lipids. Based on HDL's ability to interact with almost all cells and transport and deliver fat-soluble cargo, HDL has the remarkable capacity to affect a wide variety of endocrine-like systems. In this review, we characterize HDL's unique cargo and address the functional relevance and consequences of HDL transport and delivery of noncholesterol molecules to recipient cells and tissues.

Entities:  

Keywords:  extracellular miRNA; microRNA; small RNA carrier

Mesh:

Substances:

Year:  2013        PMID: 23515282      PMCID: PMC3927467          DOI: 10.1194/jlr.R035964

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  93 in total

1.  Lipophilic antioxidants and polyunsaturated fatty acids in lipoprotein classes: distribution and interaction.

Authors:  V H Sunesen; C Weber; G Hølmer
Journal:  Eur J Clin Nutr       Date:  2001-02       Impact factor: 4.016

2.  Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology.

Authors:  M G Korman; A F Hofmann; W H Summerskill
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

3.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Authors:  Stephen J Nicholls; H Bryan Brewer; John J P Kastelein; Kathryn A Krueger; Ming-Dauh Wang; Mingyuan Shao; Bo Hu; Ellen McErlean; Steven E Nissen
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

4.  Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation.

Authors:  Andrew J Murphy; Kevin J Woollard; Andreas Suhartoyo; Roslynn A Stirzaker; James Shaw; Dmitri Sviridov; Jaye P F Chin-Dusting
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

5.  Serum concentrations and excretion of bile acids in cirrhosis.

Authors:  G Jönsson; G Hedenborg; O Wisén; A Norman
Journal:  Scand J Clin Lab Invest       Date:  1992-11       Impact factor: 1.713

6.  High-density lipoprotein reduces the human monocyte inflammatory response.

Authors:  Andrew J Murphy; Kevin J Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A Stirzaker; Sally P A McCormick; Alan T Remaley; Dmitri Sviridov; Jaye Chin-Dusting
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

7.  High-density lipoprotein-associated alpha-tocopherol uptake by human retinal pigment epithelial cells (ARPE-19 Cells): the irrelevance of scavenger receptor class B, type I.

Authors:  Shin-ichi Akanuma; Atsushi Yamamoto; Shun Okayasu; Masanori Tachikawa; Ken-ichi Hosoya
Journal:  Biol Pharm Bull       Date:  2009-06       Impact factor: 2.233

8.  Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism.

Authors:  Norma Marchesini; Chiara Luberto; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

Review 9.  Lipoprotein-associated estrogens.

Authors:  Matti J Tikkanen; Veera Vihma; Matti Jauhiainen; Anna Höckerstedt; Hannamaarit Helisten; Maija Kaamanen
Journal:  Cardiovasc Res       Date:  2002-11       Impact factor: 10.787

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  30 in total

Review 1.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Authors:  G M Anantharamaiah; Dennis Goldberg
Journal:  Clin Lipidol       Date:  2015-01-01

Review 3.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

Review 4.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

5.  Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.

Authors:  James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden
Journal:  J Clin Lipidol       Date:  2018-01-12       Impact factor: 4.766

6.  Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Authors:  Parag H Joshi; Peter P Toth; Seth T Lirette; Michael E Griswold; Joseph M Massaro; Seth S Martin; Michael J Blaha; Krishnaji R Kulkarni; Arif A Khokhar; Adolfo Correa; Ralph B D'Agustino; Steven R Jones
Journal:  Eur J Prev Cardiol       Date:  2014-07-25       Impact factor: 7.804

7.  High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.

Authors:  Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley
Journal:  Immunology       Date:  2016-08-28       Impact factor: 7.397

8.  High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men.

Authors:  Maryam Zaid; Akira Fujiyoshi; Katsuyuki Miura; Robert D Abbott; Tomonori Okamura; Naoyuki Takashima; Sayuki Torii; Yoshino Saito; Takashi Hisamatsu; Naoko Miyagawa; Takayoshi Ohkubo; Aya Kadota; Akira Sekikawa; Hiroshi Maegawa; Yasuyuki Nakamura; Kenichi Mitsunami; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2015-01-31       Impact factor: 5.162

Review 9.  The role of miRNAs in cardiovascular disease risk factors.

Authors:  Joy N Jones Buie; Andrew J Goodwin; James A Cook; Perry V Halushka; Hongkuan Fan
Journal:  Atherosclerosis       Date:  2016-09-22       Impact factor: 5.162

10.  HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.

Authors:  Fatiha Tabet; Kasey C Vickers; Luisa F Cuesta Torres; Carrie B Wiese; Bassem M Shoucri; Gilles Lambert; Claire Catherinet; Leonel Prado-Lourenco; Michael G Levin; Seth Thacker; Praveen Sethupathy; Philip J Barter; Alan T Remaley; Kerry-Anne Rye
Journal:  Nat Commun       Date:  2014-02-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.